We are live on ! Find out more
IBRX icon

ImmunityBio
IBRX

126 hedge funds and large institutions have $311M invested in ImmunityBio in 2021 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 51 increasing their positions, 26 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

96% more repeat investments, than reductions

Existing positions increased: 51 | Existing positions reduced: 26

25% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 16

0.93% more ownership

Funds ownership: 7.23% → 8.16% (+0.93%)

1% more funds holding

Funds holding: 125 → 126 (+1)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

20% less capital invested

Capital invested by funds: $390M → $311M (-$78.7M)

61% less call options, than puts

Call options by funds: $5.03M | Put options by funds: $13M

Holders
126
Holders Change
+1
Holders Change %
+0.8%
% of All Funds
2.21%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
20
Increased
51
Reduced
26
Closed
16
Calls
$5.03M
Puts
$13M
Net Calls
-$7.96M
Net Calls Change
+$3.73M

Top Buyers

1
Vanguard Group
Vanguard Group
Pennsylvania
+$16.2M
2
State Street
State Street
Massachusetts
+$12.4M
3
JP Morgan Chase
JP Morgan Chase
New York
+$6.3M
4
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$3.23M
5
BlackRock
BlackRock
New York
+$3.06M

Top Sellers

1
First Trust Advisors
First Trust Advisors
Illinois
-$3.57M
2
N
Nuveen
North Carolina
-$3.43M
3
CSS
Cubist Systematic Strategies
Connecticut
-$1.43M
4
Citigroup
Citigroup
New York
-$1.27M
5
EGM
Engineers Gate Manager
New York
-$1.25M
Name Holding Trade Value Shares
Change 		Change in
Stake
WPA
51
Winning Points Advisors
Florida
$428K +$27.3K +2,483 +6%
UBS AM
52
UBS AM
Illinois
$420K +$189K +17,217 +66%
Invesco
53
Invesco
Georgia
$399K +$8.14K +740 +2%
Manulife (Manufacturers Life Insurance)
54
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$394K -$22.9K -2,083 -5%
DekaBank Deutsche Girozentrale
55
DekaBank Deutsche Girozentrale
Germany
$389K – – –
AIG
56
American International Group
New York
$364K -$1.06K -96 -0.3%
GH
57
GAM Holding
Switzerland
$324K – – –
William Blair & Company
58
William Blair & Company
Illinois
$321K +$88K +8,000 +32%
Osaic Holdings
59
Osaic Holdings
Arizona
$309K +$207K +18,783 +144%
Legal & General Group
60
Legal & General Group
United Kingdom
$301K +$204K +18,555 +149%
CSS
61
Cubist Systematic Strategies
Connecticut
$282K -$1.43M -129,778 -82%
Axa
62
Axa
France
$281K +$317K +28,800 New
Ameriprise
63
Ameriprise
Minnesota
$269K -$5.72K -520 -2%
VOYA Investment Management
64
VOYA Investment Management
Georgia
$258K – – –
PPA
65
Parametric Portfolio Associates
Washington
$250K +$55.8K +5,069 +25%
Victory Capital Management
66
Victory Capital Management
Texas
$248K +$11.4K +1,033 +4%
State Board of Administration of Florida Retirement System
67
State Board of Administration of Florida Retirement System
Florida
$218K +$59.2K +5,380 +32%
Principal Financial Group
68
Principal Financial Group
Iowa
$211K -$38.6K -3,510 -14%
ASRS
69
Arizona State Retirement System
Arizona
$204K +$116K +10,545 +102%
VF
70
Virtu Financial
New York
$196K +$221K +20,127 New
BAM
71
Berkshire Asset Management
Pennsylvania
$195K – – –
Mitsubishi UFJ Asset Management
72
Mitsubishi UFJ Asset Management
Japan
$192K – – –
Franklin Resources
73
Franklin Resources
California
$190K +$215K +19,500 New
MLICM
74
Metropolitan Life Insurance Company (MetLife)
New York
$187K – – –
MIM
75
MetLife Investment Management
New Jersey
$162K -$92.8K -8,431 -34%
1 2
3
4 5

IBRX Hedge Fund Activity: Q3 2021 in Review

126 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in ImmunityBio (IBRX) for Q3 2021, worth a combined $311M — down 20% from $390M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new IBRX positions and 16 closed out — a net gain of 4 holders — while 51 added to existing stakes and 26 trimmed.

The largest buyer was Vanguard Group, adding an estimated $16.2M. The largest seller was First Trust Advisors, exiting entirely with an estimated $3.57M sold.

  • 126 institutional investors held ImmunityBio (IBRX) as of Q3 2021, up from 125 in Q2 2021.
  • Funds reported $311M of ImmunityBio stock for Q3 2021, down 20% quarter-over-quarter.
  • 20 funds opened new ImmunityBio positions in Q3 2021 and 16 closed out, a net change of +4 holders.
  • The largest ImmunityBio buyer in Q3 2021 was Vanguard Group, an estimated $16.2M added.
  • The largest ImmunityBio seller in Q3 2021 was First Trust Advisors, an estimated $3.57M sold.

Based on aggregated 13F filings for Q3 2021.